William Blair Comments on Exagen's Q2 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN - Free Report) - Investment analysts at William Blair lowered their Q2 2025 earnings per share (EPS) estimates for shares of Exagen in a research report issued to clients and investors on Monday, May 5th. William Blair analyst A. Brackmann now anticipates that the company will post earnings per share of ($0.18) for the quarter, down from their previous estimate of ($0.16). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen's Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.61) EPS and FY2026 earnings at ($0.25) EPS.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 target price on shares of Exagen in a research note on Monday, January 13th. BTIG Research reissued a "buy" rating on shares of Exagen in a report on Wednesday.

Exagen Stock Performance

Shares of NASDAQ XGN traded down $0.45 during midday trading on Thursday, hitting $5.71. 357,579 shares of the company's stock were exchanged, compared to its average volume of 108,667. Exagen has a twelve month low of $1.49 and a twelve month high of $7.20. The firm has a market cap of $102.79 million, a P/E ratio of -6.07 and a beta of 1.50. The stock's 50 day moving average price is $4.54 and its 200-day moving average price is $4.12. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05.

Exagen (NASDAQ:XGN - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). The business had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same period in the previous year, the business earned ($0.19) EPS.

Institutional Investors Weigh In On Exagen

Institutional investors and hedge funds have recently modified their holdings of the stock. Corient Private Wealth LLC acquired a new stake in shares of Exagen during the fourth quarter worth $45,000. Virtu Financial LLC acquired a new stake in Exagen during the 4th quarter worth about $46,000. Marshall Wace LLP purchased a new stake in Exagen during the fourth quarter valued at about $66,000. Northern Trust Corp boosted its holdings in shares of Exagen by 16.7% in the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after buying an additional 2,630 shares during the period. Finally, Huntleigh Advisors Inc. increased its position in shares of Exagen by 16.8% in the first quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company's stock worth $298,000 after acquiring an additional 11,939 shares in the last quarter. Institutional investors and hedge funds own 75.25% of the company's stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).